Changchun Genescience Pharma received NMPA clearance to initiate clinical trials of Gensci‑136, a dual APRIL/BAFF antagonist formulated for injection to treat immunoglobulin A nephropathy (IgAN). The clearance allows the company to move the candidate into human testing in China. Gensci‑136 targets two B‑cell survival pathways implicated in IgAN pathogenesis; dual APRIL/BAFF blockade is positioned to modulate pathogenic IgA production. The NMPA clearance is an early regulatory milestone that could accelerate development timelines in China and support potential global filings if clinical data are positive. Sponsors and partners will watch safety and biomarker readouts closely, given the immunomodulatory mechanism and the need to demonstrate renal outcomes that translate into meaningful clinical benefit.